Elevated levels of mitochondrion-associated autophagy inhibitor LRPPRC are associated with poor prognosis in patients with prostate cancer

Cancer

Volumn 120, Issue 8, 2014, Pages 1228-1236

  Jiang, Xianhan ^a   Li, Xun ^a   Huang, Hai ^b   Jiang, Funeng ^c   Lin, Zhuoyuan ^c   He, Huichan ^c   Chen, Yanru ^c   Yue, Fei ^a   Zou, Jing ^a   He, Yongzhong ^a   You, Pan ^a   Wang, Wenwei ^b   Yang, Weiqing ^a   Zhao, Haibo ^a   Lai, Yiming ^b   Wang, Fen ^a   Zhong, Weide ^c   Liu, Leyuan ^a  

^a GUANGZHOU MEDICAL UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

autophagy; benign prostatic hyperplasia; biomarker; cancer prognosis; leucine rich pentatricopeptide repeat motif containing protein (LRPPRC); mitochondria; phosphatase and tensin homolog (PTEN); prostate adenocarcinomas; prostatic intraepithelial neoplasia

Indexed keywords

LEUCINE RICH PENTATRICOPEPTIDE REPEAT MOTIF CONTAINING PROTEIN; MEMBRANE PROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; CANCER DIAGNOSIS; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLOW UP; GLEASON SCORE; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; SURVIVAL RATE; SURVIVAL TIME;

AUTOPHAGY; BENIGN PROSTATIC HYPERPLASIA; BIOMARKER; CANCER PROGNOSIS; LEUCINE-RICH PENTATRICOPEPTIDE REPEAT MOTIF-CONTAINING PROTEIN (LRPPRC); MITOCHONDRIA; PHOSPHATASE AND TENSIN HOMOLOG (PTEN); PROSTATE ADENOCARCINOMAS; PROSTATIC INTRAEPITHELIAL NEOPLASIA;

AGED; AGED, 80 AND OVER; ANIMALS; AUTOPHAGY; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; PROGNOSIS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PTEN PHOSPHOHYDROLASE;

EID: 84898044364     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28551     Document Type: Article

References (49)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63: 11-30.
2. Baade PD, Youlden DR, Krnjacki LJ,. International epidemiology of prostate cancer: geographical distribution and secular trends. Mol Nutr Food Res. 2009; 53: 171-184.
3. Lilja H, Ulmert D, Vickers AJ,. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008; 8: 268-278.
4. Velonas VM, Woo HH, Remedios CG, Assinder SJ,. Current status of biomarkers for prostate cancer. Int J Mol Sci. 2013; 14: 11034-11060.
5. Froehner M, Abolmaali N, Wirth MP,. Prostate-specific antigen-negative prostate cancer recurrence? Urology. 2013; 81: e17-e18.
6. Bucerius J, Ahmadzadehfar H, Hortling N, Joe AY, Palmedo H, Biersack HJ,. Incidental diagnosis of a PSA-negative prostate cancer by 18FDG PET/CT in a patient with hypopharyngeal cancer. Prostate Cancer Prostatic Dis. 2007; 10: 307-310.
7. Mizushima N, Levine B, Cuervo AM, Klionsky DJ,. Autophagy fights disease through cellular self-digestion. Nature. 2008; 451: 1069-1075.
8. Liu L, Xie R, Nguyen S, Ye M, McKeehan WL,. Robust autophagy/mitophagy persists during mitosis. Cell Cycle. 2009; 8: 1616-1620.
9. Terman A, Gustafsson B, Brunk UT,. The lysosomal-mitochondrial axis theory of postmitotic aging and cell death. Chem Biol Interact. 2006; 163: 29-37.
10. Geisler S, Holmstrom KM, Skujat D, et al. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol. 2010; 12: 119-131.
11. Matsuda N, Sato S, Shiba K, et al. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J Cell Biol. 2010; 189: 211-221.
12. Narendra D, Kane LA, Hauser DN, Fearnley IM, Youle RJ,. p62/SQSTM1 is required for Parkin-induced mitochondrial clustering but not mitophagy; VDAC1 is dispensable for both. Autophagy. 2010; 6: 1090-1106.
13. Wang S, Gao J, Lei Q, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell. 2003; 4: 209-221.
14. Liu L, Amy V, Liu G, McKeehan WL,. Novel complex integrating mitochondria and the microtubular cytoskeleton with chromosome remodeling and tumor suppressor RASSF1 deduced by in silico homology analysis, interaction cloning in yeast, and colocalization in cultured cells. In Vitro Cell Dev Biol Anim. 2002; 38: 582-594.
15. Liu L, McKeehan WL,. Sequence analysis of LRPPRC and its SEC1 domain interaction partners suggest roles in cytoskeletal organization, vesicular trafficking, nucleocytosolic shuttling, and chromosome activity. Genomics. 2002; 79: 124-136.
16. Zou J, Yue F, Jiang X, Li W, Yi J, Liu L,. Mitochondrion-associated protein LRPPRC suppresses the initiation of basal levels of autophagy via enhancing Bcl-2 stability. Biochem J. 2013; 454: 447-457.
17. Mootha VK, Lepage P, Miller K, et al. Identification of a gene causing human cytochrome c oxidase deficiency by integrative genomics. Proc Natl Acad Sci USA. 2003; 100: 605-610.
18. Liu L, Vo A, Liu G, McKeehan WL,. Putative tumor suppressor RASSF1 interactive protein and cell death inducer C19ORF5 is a DNA binding protein. Biochem Biophys Res Commun. 2005; 332: 670-676.
19. Kayaba H, Hirokawa M, Watanabe A, et al. Serum markers of graft-versus-host disease after bone marrow transplantation. J Allergy Clin Immunol. 2000; 106 (1 pt 2): S40-S44.
20. Schoenfeld TA, McKerracher L, Obar R, Vallee RB,. MAP 1A and MAP 1B are structurally related microtubule associated proteins with distinct developmental patterns in the CNS. J Neurosci. 1989; 9: 1712-1730.
21. Xie R, Nguyen S, McKeehan K, Wang F, McKeehan WL, Liu L,. Microtubule-associated protein 1S (MAP1S) bridges autophagic components with microtubules and mitochondria to affect autophagosomal biogenesis and degradation. J Biol Chem. 2011; 286: 10367-10377.
22. Xie R, Wang F, McKeehan WL, Liu L,. Autophagy enhanced by microtubule- and mitochondrion-associated MAP1S suppresses genome instability and hepatocarcinogenesis. Cancer Res. 2011; 71: 7537-7546.
23. Liu L, McKeehan WL, Wang F, Xie R,. MAP1S enhances autophagy to suppress tumorigenesis. Autophagy. 2012; 8: 278-280.
24. Cooper MP, Qu L, Rohas LM, et al. Defects in energy homeostasis in Leigh syndrome French Canadian variant through PGC-1alpha/LRP130 complex. Genes Dev. 2006; 20: 2996-3009.
25. Cooper MP, Uldry M, Kajimura S, Arany Z, Spiegelman BM,. Modulation of PGC-1 coactivator pathways in brown fat differentiation through LRP130. J Biol Chem. 2008; 283: 31960-31967.
26. Xu F, Addis JB, Cameron JM, Robinson BH,. LRPPRC mutation suppresses cytochrome oxidase activity by altering mitochondrial RNA transcript stability in a mouse model. Biochem J. 2012; 441: 275-283.
27. Mili S, Pinol-Roma S,. LRP130, a pentatricopeptide motif protein with a noncanonical RNA-binding domain, is bound in vivo to mitochondrial and nuclear RNAs. Mol Cell Biol. 2003; 23: 4972-4982.
28. Mili S, Shu HJ, Zhao Y, Pinol-Roma S,. Distinct RNP complexes of shuttling hnRNP proteins with pre-mRNA and mRNA: candidate intermediates in formation and export of mRNA. Mol Cell Biol. 2001; 21: 7307-7319.
29. Xu F, Morin C, Mitchell G, Ackerley C, Robinson BH,. The role of the LRPPRC (leucine-rich pentatricopeptide repeat cassette) gene in cytochrome oxidase assembly: mutation causes lowered levels of COX (cytochrome c oxidase) I and COX III mRNA. Biochem J. 2004; 382 (pt 1): 331-336.
30. Sondheimer N, Fang JK, Polyak E, Falk MJ, Avadhani NG,. Leucine-rich pentatricopeptide-repeat containing protein regulates mitochondrial transcription. Biochemistry. 2010; 49: 7467-7473.
31. Ruzzenente B, Metodiev MD, Wredenberg A, et al. LRPPRC is necessary for polyadenylation and coordination of translation of mitochondrial mRNAs. EMBO J. 2012; 31: 443-456.
32. Sasarman F, Brunel-Guitton C, Antonicka H, Wai T, Shoubridge EA,; LSFC Consortium. LRPPRC and SLIRP interact in a ribonucleoprotein complex that regulates posttranscriptional gene expression in mitochondria. Mol Biol Cell. 2010; 21: 1315-1323.
33. Liu L, Sanosaka M, Lei S, et al. LRP130 protein remodels mitochondria and stimulates fatty acid oxidation. J Biol Chem. 2011; 286: 41253-41264.
34. Gohil VM, Nilsson R, Belcher-Timme CA, Luo B, Root DE, Mootha VK,. Mitochondrial and nuclear genomic responses to loss of LRPPRC expression. J Biol Chem. 2010; 285: 13742-13747.
35. Jin C, McKeehan K, Wang F,. Transgenic mouse with high Cre recombinase activity in all prostate lobes, seminal vesicle, and ductus deferens. Prostate. 2003; 57: 160-164.
36. Tian T, Ikeda J, Wang Y, et al. Role of leucine-rich pentatricopeptide repeat motif-containing protein (LRPPRC) for anti-apoptosis and tumourigenesis in cancers. Eur J Cancer. 2012; 48: 2462-2473.
37. Michaud M, Barakat S, Magnard S, Rigal D, Baggetto LG,. Leucine-rich protein 130 contributes to apoptosis resistance of human hepatocarcinoma cells. Int J Oncol. 2011; 38: 169-178.
38. Lessene G, Czabotar PE, Colman PM,. BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov. 2008; 7: 989-1000.
39. Catz SD, Johnson JL,. BCL-2 in prostate cancer: a minireview. Apoptosis. 2003; 8: 29-37.
40. Mathupala SP, Ko YH, Pedersen PL,. The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies. Biochim Biophys Acta. 2010; 1797: 1225-1230.
41. Parr RL, Mills J, Harbottle A, et al. Mitochondria, prostate cancer, and biopsy sampling error. Discov Med. 2013; 15: 213-220.
42. Herrmann PC, Gillespie JW, Charboneau L, et al. Mitochondrial proteome: altered cytochrome c oxidase subunit levels in prostate cancer. Proteomics. 2003; 3: 1801-1810.
43. Fulda S, Galluzzi L, Kroemer G,. Targeting mitochondria for cancer therapy. Nat Rev Drug Discov. 2010; 9: 447-464.
44. Dias N, Bailly C,. Drugs targeting mitochondrial functions to control tumor cell growth. Biochem Pharmacol. 2005; 70: 1-12.
45. Kroemer G, Galluzzi L, Brenner C,. Mitochondrial membrane permeabilization in cell death. Physiol Rev. 2007; 87: 99-163.
46. Marzo I, Brenner C, Zamzami N, et al. Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science. 1998; 281: 2027-2031.
47. Magda D, Miller RA,. Motexafin gadolinium: a novel redox active drug for cancer therapy. Semin Cancer Biol. 2006; 16: 466-476.
48. Ross K, Rudel T, Kozjak-Pavlovic V,. TOM-independent complex formation of Bax and Bak in mammalian mitochondria during TNFalpha-induced apoptosis. Cell Death Differ. 2009; 16: 697-707.
49. Simons AL, Ahmad IM, Mattson DM, Dornfeld KJ, Spitz DR,. 2-Deoxy-D-glucose combined with cisplatin enhances cytotoxicity via metabolic oxidative stress in human head and neck cancer cells. Cancer Res. 2007; 67: 3364-3370.